Abstract 1540
Background
Merkel cell carcinoma (MCC) is a rare, aggressive, cutaneous neuroendocrine tumor. Merkel cell polyomavirus (MCPyV) is detected in the majority of MCCs while MCPyV-negative cases are thought to arise through progressive accumulation of ultraviolet-light induced somatic mutations. In a non-selected cohort of stage IV MCC patients, treatment with Avelumab (an anti-PD-L1 monoclonal antibody), showed durable responses in less than a third of patients, regardless of their PD-L1 or MCV status. We hypothesized that there are significant differences in other predictors of response to I-O therapy in MCC related to their oncogenic origins.
Methods
48 MCC samples were analyzed for the presence of MCPyV using immunohistochemistry for detection of the large T-antigen (CM2B4 clone). Biomarkers of I-O therapy response included: expression of PD-L1 (IHC), total mutational burden (TMB) and microsatellite instability (MSI).
Results
Overall, MCPyV was detected in 18/48 cases using IHC (37.5%). In MCPyV-positive cases (N = 9) average TMB was 6/Mb (range 4-11/Mb), while MCPyV-negative cases (N = 21) had a significantly (p < 0.0001) higher average TMB of 25/Mb (range 4-68/Mb). No microsatellite instability was detected in any of the cases (0/22). The most commonly mutated gene in MCPyV-negative cohort was TP53 detected in 20 cases, with co-mutation of RB1 in 11 cases. Only one pathogenic mutation (ARID1A) was detected in any of the 9 MCPyV-positive cases. A single (MCPyV-positive) case exhibited PD-L1 expression in 5% of tumor cells.
Conclusions
MCPyV associated MCC was present in a significantly lower proportion of cases in our data set (37.5%) than has been reported in the general population (70-80%), potentially due to preselection of advanced disease cases. Successes of Avelumab therapy in MCC may be related to the high mutational load in MCPyV-negative cases and mediated through PD-L1+ immune cell infiltrate (IC) influence on effector (PD-1) lymphocytes, or some other mechanism. Further analysis of the status of these (and potentially other) biomarkers of response to immune check point inhibitors is recommended to refine the subgroups of patients responding to therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Caris Life Sciences.
Funding
Caris Life Sciences.
Disclosure
Z. Gatalica: Leadership role: Caris Life Sciences. J. Xiu: Leadership role, employment: Caris Life Sciences. J. Swensen: Leadership role, employment: Caris Life Sciences. All other authors have declared no conflicts of interest.
Resources from the same session
2743 - The Impact of Targeted Therapies and Immunotherapy in Melanoma Brain Metastases: a Systematic Review and Meta-Analysis
Presenter: Mario Mandala
Session: Poster Display session 3
Resources:
Abstract
5479 - Intracranial Anti-Tumor Activity in Melanoma Brain Metastases with Encorafenib Plus Binimetinib: A Multicenter, Retrospective Analysis
Presenter: Jose Lutzky
Session: Poster Display session 3
Resources:
Abstract
3560 - Outcomes of Patients with Melanoma Brain Metastases (MBM) Treated with Standard of Care Therapy After Being Excluded from MBM-Specific Clinical Trials
Presenter: Kourtney Holbrook
Session: Poster Display session 3
Resources:
Abstract
3175 - The analysis of current treatment outcomes in melanoma patients with brain metastases
Presenter: Joanna Placzke
Session: Poster Display session 3
Resources:
Abstract
4550 - A multivariate model to define prognostic groups among patients with melanoma brain metastases: a 10-year retrospective cohort study
Presenter: Giacomo Pelizzari
Session: Poster Display session 3
Resources:
Abstract
4191 - The immune landscape of melanoma significantly influences survival in patients with highly mutated tumors.
Presenter: Robert Ferguson
Session: Poster Display session 3
Resources:
Abstract
1625 - Final Results from Phase II of Combination with Canerpaturev (formerly HF10), an Oncolytic Viral Immunotherapy, and Ipilimumab in Unresectable or Metastatic Melanoma in 2nd-or later line treatment
Presenter: Kenji Yokota
Session: Poster Display session 3
Resources:
Abstract
5346 - Evaluating polygenic risk score prediction model for melanoma prognosis
Presenter: Miriam Potrony
Session: Poster Display session 3
Resources:
Abstract
5477 - Impact of sarcopenia in patients with metastatic melanoma treated with immunotherapy
Presenter: Maria Grazia Vitale
Session: Poster Display session 3
Resources:
Abstract
3469 - Ancillary evaluation of systemic immune antitumor response (SIAR) and tumor growth rate (TGR) of patients (pts) with metastatic melanoma (MM) treated with radiotherapy (RT) combined with ipilimumab (ipi) in the phase 1 study Mel-Ipi-Rx.
Presenter: Celine Boutros
Session: Poster Display session 3
Resources:
Abstract